BioSpace News Archive

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its Noctiva™ brand.

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™).

Moderna, Inc. announced its global public health strategy through four new initiatives aimed at advancing mRNA vaccines for the prevention of infectious diseases.

Akeso, Inc. announced that the CDE of China’s National Medical Products Administration has approved the IND application for the initiation of the open-label, multicenter phase II trial in China using Cadonilimab in combination with Docetaxel in patients with advanced NSCLC which progressed on combination therapy of PD-1/L1 inhibitor and platinum-based doublet chemotherapy.

Viemed Healthcare, Inc., a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, reported its financial results for the three months and year ended December 31, 2021.

Liminal BioSciences Inc., announced that on March 4, 2022, it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company is not in compliance with the minimum bid price requirement of US$1.00 per share under the Nasdaq Listing Rules.

Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) a pivotal Phase III study of investigational renal (kidney) cancer imaging agent TLX250-CDx has dosed 252 patients, the target enrolment for the study.

Southwest Research Institute will collaborate with University of Michigan to use additive manufacturing and machine learning to create an advanced burner that will eliminate 99.5% of the methane encountered during oil production.

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2021 and provided an update on its corporate activities and product pipeline.

Rakuten Medical, Inc. has elected to discontinue use of the name “Illuminox,” and to start using a new, evolved name “Alluminox™" for our proprietary, anti-cancer, photoimmunotherapy technology platform, which is comprised of drug, medical device, and other related technologies.